Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A role for IL-33–activated ILC2s in eosinophilic vasculitis
Maya E. Kotas, Jérémie Dion, Steven Van Dyken, Roberto R. Ricardo-Gonzalez, Claire J. Danel, Camille Taillé, Luc Mouthon, Richard M. Locksley, Benjamin Terrier
Maya E. Kotas, Jérémie Dion, Steven Van Dyken, Roberto R. Ricardo-Gonzalez, Claire J. Danel, Camille Taillé, Luc Mouthon, Richard M. Locksley, Benjamin Terrier
View: Text | PDF
Research Article Immunology

A role for IL-33–activated ILC2s in eosinophilic vasculitis

  • Text
  • PDF
Abstract

Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare but serious disease with poorly understood mechanisms. Here, we report that patients with EGPA have elevated levels of TSLP, IL-25, and soluble ST2, which are well-characterized cytokine “alarmins” that activate or modulate type 2 innate lymphoid cells (ILC2s). Patients with active EGPA have a concurrent reduction in circulating ILC2s, suggesting a role for ILC2s in the pathogenesis of this disease. To explore the mechanism of these findings in patients, we established a model of EGPA in which active vasculitis and pulmonary hemorrhage were induced by IL-33 administration in predisposed, hypereosinophilic mice. In this model, induction of pulmonary hemorrhage and vasculitis was dependent on ILC2s and signaling through IL4Rα. In the absence of IL4Rα or STAT6, IL-33–treated mice had less vascular leak and pulmonary edema, less endothelial activation, and reduced eotaxin production, cumulatively leading to a reduction of pathologic eosinophil migration into the lung parenchyma. These results offer a mouse model for use in future mechanistic studies of EGPA, and they suggest that IL-33, ILC2s, and IL4Rα signaling may be potential targets for further study and therapeutic targeting in patients with EGPA.

Authors

Maya E. Kotas, Jérémie Dion, Steven Van Dyken, Roberto R. Ricardo-Gonzalez, Claire J. Danel, Camille Taillé, Luc Mouthon, Richard M. Locksley, Benjamin Terrier

×

Figure 6

IL4Rα signaling facilitates eosinophil egress into tissue through recruitment and vascular activation.

Options: View larger image (or click on image) Download as PowerPoint
IL4Rα signaling facilitates eosinophil egress into tissue through recrui...
(A) Extravascular (unlabeled) eosinophils (single, live, CD45+, CD11b+, CD125–, SiglecF+, SSChi cells) from saline-treated or IL-33–treated lungs. n = 3 mice/group. (B) Eotaxin measured from serum of untreated mice as indicated. n = 3–9 mice/group. (C) Eotaxin measured from BAL or (D) serum of saline-treated or IL-33–treated WT or IL4Rα–/– mice. n = 3–6 mice/group. (E) Eotaxin measured from BAL or (F) serum of saline-treated or IL-33–treated WT or ILC2del mice. n = 6–7 mice/group. Significance determined by 1-way ANOVA with Sidak (A, C, and D) Dunnett’s (B) or Tukey (E and F) post hoc testing; ****P < 0.0001; ***P < 0.001; *P < 0.05. Data are presented as ± SEM. BAL, bronchoalveolar lavage; ILC2s, type 2 innate lymphoid cells.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts